Volltext verfügbar nach Anmeldung bzw. im Campus-Netz.
ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors
In: Business Wire (English), 2018-11-07
Online
Zeitungsartikel
Zugriff:
ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced updated results from its Phase 1 ALX148 solid tumor program in patients with advanced malignancy at SITC’s 33rd Annual Meeting. The data will be further discussed in an oral presentation. [ABSTRACT FROM PUBLISHER]
Titel: |
ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors
|
---|---|
Autor/in / Beteiligte Person: | Oncology, ALX |
Zeitschrift: | Business Wire (English), 2018-11-07 |
Veröffentlichung: | 2018 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|